1. Date of download: 9/19/2016 From: Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C Ann Intern Med. 2000;132(4):296-305. doi:10.7326/0003-4819-132-4-200002150-00008 Schematic diagram of the hepatitis C virus genome.5′UTR3′XRThe location of HCV genes, proposed functions of gene products, and the 5′ and 3′ untranslated regions ( and ) are shown. Numbering refers to nucleotide positions of genes. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

2. Date of download: 9/19/2016 From: Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C Ann Intern Med. 2000;132(4):296-305. doi:10.7326/0003-4819-132-4-200002150-00008 Components of the antiviral immune response.HCVAlthough the hepatocyte is depicted as the target cell of hepatitis C virus ( )-specific immune response here, other cells, including dendritic cells and macrophages, are also important in antigen presentation to the immune system. CTL = cytotoxic T cell; IL = interleukin; MHC = major histocompatibility complex; TCR = T-cell receptor; Th = T helper; Th1 = helper T cells with a type 1 cytokine profile; Th2 = helper T cells with a type 2 cytokine profile; TNF = tumor necrosis factor. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

3. Date of download: 9/19/2016 From: Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C Ann Intern Med. 2000;132(4):296-305. doi:10.7326/0003-4819-132-4-200002150-00008 Survival curves comparing patients with non-A, non-B transfusion-associated, predominantly type C hepatitis (solid line); matched transfusion recipients without hepatitis (controls) (dashed line); and the general U.S. population (dotted line).Survival of 100% is shown as 1 on the y axis. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

4. Date of download: 9/19/2016 From: Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C Ann Intern Med. 2000;132(4):296-305. doi:10.7326/0003-4819-132-4-200002150-00008 Rates of virologic response in patients with chronic hepatitis C treated with interferon-α for 24 weeks (IFN 24 wk) or 48 weeks (IFN 48 wk) or interferon-α plus ribavirin for 24 weeks (IFN and RBV 24 wk) or 48 weeks (IFN and RBV 48 wk).(49, 51)The total height of the bars represents the end-of-treatment response rate; the white portion represents the sustained response rate. Data are shown for 1744 patients (the number in each treatment group is given in parentheses) from two large prospective clinical trials. Numbers at the top of the bars represent exact percentages. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

5. Date of download: 9/19/2016 From: Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C Ann Intern Med. 2000;132(4):296-305. doi:10.7326/0003-4819-132-4-200002150-00008 Rates of sustained virologic response in patients with chronic hepatitis C treated with interferon-α for 24 weeks (IFN 24 wk) or 48 weeks (IFN 48 wk) or interferon-α plus ribavirin for 24 weeks (IFN and RBV 24 wk) or 48 weeks (IFN and RBV 48 wk), by viral genotype.(49, 51)The white bars represent patients with genotype 1 and the few patients with genotypes 4, 5, and 6; the striped bars represent patients with genotypes 2 and 3. Data are shown for 1744 patients (the number in each treatment group is given in parentheses) from two large prospective clinical trials. Numbers at the top of the bars represent exact percentages. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians